MLL/KMT2A rearrangement constitutes more than 70% of infant acute lymphoblastic leukemia (ALL), ~35–50% of infant acute myeloid leukemia (AML), and 5–10% of adult AML cases. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.